Ashwin N Ananthakrishnan1, Andrew Cagan, Tianxi Cai, Vivian S Gainer, Stanley Y Shaw, Guergana Savova, Susanne Churchill, Elizabeth W Karlson, Shawn N Murphy, Katherine P Liao, Isaac Kohane. 1. *Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts; †Harvard Medical School, Boston, Massachusetts; ‡Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; §Research IS and Computing, Partners HealthCare, Charlestown, Massachusetts; ‖Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts; ¶Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts; **Children's Hospital Informatics Program, Boston Children's Hospital, Boston, Massachusetts; ††i2b2 National Center for Biomedical Computing, Brigham and Women's Hospital, Boston, Massachusetts; ‡‡Division of Rheumatology, Allergy and Immunology, Brigham and Women's Hospital, Boston, Massachusetts; §§Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts; and ‖‖Children's Hospital Boston, Boston, Massachusetts.
Abstract
BACKGROUND: Electronic health records, increasingly a part of healthcare, provide a wealth of untapped narrative free text data that have the potential to accurately inform clinical outcomes. METHODS: From a validated cohort of patients with Crohn's disease or ulcerative colitis, we identified patients with ≥1 coded or narrative mention of monoclonal antibodies to tumor necrosis factor α. Chart review by ascertained true use of therapy, time of initiation, and cessation of treatment, and also clinical response stratified as nonresponse, partial, or complete response at 1 year. Internal consistency was assessed in an independent validation cohort. RESULTS: A total of 3087 patients had a mention of an antibodies to tumor necrosis factor α. Actual therapy initiation was within 60 days of the first coded mention in 74% of patients. In the derivation cohort, 18% of antibodies to tumor necrosis factor α starts were classified as nonresponse at 1 year, 21% as partial, and 56% as complete response. On multivariate analysis, the number of narrative mentions of diarrhea (odds ratio 1.08; 95% confidence interval, 1.02-1.14) and fatigue (odds ratio 1.16; 95% confidence interval, 1.02-1.32) was independently associated with nonresponse at 1 year (area under the curve 0.82). A likelihood of nonresponse score comprising a weighted sum of both demonstrated a good dose-response relationship across nonresponders (2.18), partial (1.20), and complete (0.50) responders (P < 0.0001) and correlated well with need for surgery or hospitalizations. CONCLUSIONS: Narrative data in an electronic health record offer considerable potential to define temporally evolving disease outcomes such as nonresponse to treatment.
BACKGROUND: Electronic health records, increasingly a part of healthcare, provide a wealth of untapped narrative free text data that have the potential to accurately inform clinical outcomes. METHODS: From a validated cohort of patients with Crohn's disease or ulcerative colitis, we identified patients with ≥1 coded or narrative mention of monoclonal antibodies to tumornecrosis factor α. Chart review by ascertained true use of therapy, time of initiation, and cessation of treatment, and also clinical response stratified as nonresponse, partial, or complete response at 1 year. Internal consistency was assessed in an independent validation cohort. RESULTS: A total of 3087 patients had a mention of an antibodies to tumornecrosis factor α. Actual therapy initiation was within 60 days of the first coded mention in 74% of patients. In the derivation cohort, 18% of antibodies to tumornecrosis factor α starts were classified as nonresponse at 1 year, 21% as partial, and 56% as complete response. On multivariate analysis, the number of narrative mentions of diarrhea (odds ratio 1.08; 95% confidence interval, 1.02-1.14) and fatigue (odds ratio 1.16; 95% confidence interval, 1.02-1.32) was independently associated with nonresponse at 1 year (area under the curve 0.82). A likelihood of nonresponse score comprising a weighted sum of both demonstrated a good dose-response relationship across nonresponders (2.18), partial (1.20), and complete (0.50) responders (P < 0.0001) and correlated well with need for surgery or hospitalizations. CONCLUSIONS: Narrative data in an electronic health record offer considerable potential to define temporally evolving disease outcomes such as nonresponse to treatment.
Authors: Ashish K Jha; Matthew F Burke; Catherine DesRoches; Maulik S Joshi; Peter D Kralovec; Eric G Campbell; Melinda B Buntin Journal: Am J Manag Care Date: 2011-12 Impact factor: 2.229
Authors: R H Perlis; D V Iosifescu; V M Castro; S N Murphy; V S Gainer; J Minnier; T Cai; S Goryachev; Q Zeng; P J Gallagher; M Fava; J B Weilburg; S E Churchill; I S Kohane; J W Smoller Journal: Psychol Med Date: 2011-06-20 Impact factor: 7.723
Authors: Ashwin N Ananthakrishnan; Tianxi Cai; Guergana Savova; Su-Chun Cheng; Pei Chen; Raul Guzman Perez; Vivian S Gainer; Shawn N Murphy; Peter Szolovits; Zongqi Xia; Stanley Shaw; Susanne Churchill; Elizabeth W Karlson; Isaac Kohane; Robert M Plenge; Katherine P Liao Journal: Inflamm Bowel Dis Date: 2013-06 Impact factor: 5.325
Authors: Lesley A Graff; Ian Clara; John R Walker; Lisa Lix; Rachel Carr; Norine Miller; Linda Rogala; Charles N Bernstein Journal: Clin Gastroenterol Hepatol Date: 2013-04-16 Impact factor: 11.382
Authors: Omri Gottesman; Helena Kuivaniemi; Gerard Tromp; W Andrew Faucett; Rongling Li; Teri A Manolio; Saskia C Sanderson; Joseph Kannry; Randi Zinberg; Melissa A Basford; Murray Brilliant; David J Carey; Rex L Chisholm; Christopher G Chute; John J Connolly; David Crosslin; Joshua C Denny; Carlos J Gallego; Jonathan L Haines; Hakon Hakonarson; John Harley; Gail P Jarvik; Isaac Kohane; Iftikhar J Kullo; Eric B Larson; Catherine McCarty; Marylyn D Ritchie; Dan M Roden; Maureen E Smith; Erwin P Böttinger; Marc S Williams Journal: Genet Med Date: 2013-06-06 Impact factor: 8.822
Authors: Marylyn D Ritchie; Joshua C Denny; Rebecca L Zuvich; Dana C Crawford; Jonathan S Schildcrout; Lisa Bastarache; Andrea H Ramirez; Jonathan D Mosley; Jill M Pulley; Melissa A Basford; Yuki Bradford; Luke V Rasmussen; Jyotishman Pathak; Christopher G Chute; Iftikhar J Kullo; Catherine A McCarty; Rex L Chisholm; Abel N Kho; Christopher S Carlson; Eric B Larson; Gail P Jarvik; Nona Sotoodehnia; Teri A Manolio; Rongling Li; Daniel R Masys; Jonathan L Haines; Dan M Roden Journal: Circulation Date: 2013-03-05 Impact factor: 29.690
Authors: Zongqi Xia; Elizabeth Secor; Lori B Chibnik; Riley M Bove; Suchun Cheng; Tanuja Chitnis; Andrew Cagan; Vivian S Gainer; Pei J Chen; Katherine P Liao; Stanley Y Shaw; Ashwin N Ananthakrishnan; Peter Szolovits; Howard L Weiner; Elizabeth W Karlson; Shawn N Murphy; Guergana K Savova; Tianxi Cai; Susanne E Churchill; Robert M Plenge; Isaac S Kohane; Philip L De Jager Journal: PLoS One Date: 2013-11-11 Impact factor: 3.240
Authors: Alyce J M Anderson; Benjamin Click; Claudia Ramos-Rivers; Dmitriy Babichenko; Ioannis E Koutroubakis; Douglas J Hartman; Jana G Hashash; Marc Schwartz; Jason Swoger; Arthur M Barrie; Michael A Dunn; Miguel Regueiro; David G Binion Journal: Dig Dis Sci Date: 2016-09-12 Impact factor: 3.199
Authors: Ashwin N Ananthakrishnan; Andrew Cagan; Tianxi Cai; Vivian S Gainer; Stanley Y Shaw; Guergana Savova; Susanne Churchill; Elizabeth W Karlson; Isaac Kohane; Katherine P Liao; Shawn N Murphy Journal: Inflamm Bowel Dis Date: 2016-04 Impact factor: 5.325
Authors: April Barnado; Robert J Carroll; Carolyn Casey; Lee Wheless; Joshua C Denny; Leslie J Crofford Journal: Arthritis Res Ther Date: 2018-04-10 Impact factor: 5.156